The European Medicines Agency (EMA) has authorized the commercialization of the GLP1 receptor agonist liraglutide 3.0 mg for patients with obesity, and semaglutide 0.25, 0.5, and 1 mg and dulaglutide 0.75 and 1.5 mg for patients with obesity and type 2 diabetes. This evidence concerns the gene GLP1R and Obesity.